Targeting the β secretase BACE1 for Alzheimer's disease therapy

摘要: Summary The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1 (BACE1), initiates the production of toxic (Aβ) that plays a crucial early part in Alzheimer's disease pathogenesis. BACE1 is prime therapeutic target for lowering cerebral Aβ concentrations disease, and clinical development inhibitors being intensely pursued. Although inhibitor drug has proven challenging, several promising have recently entered human trials. safety efficacy these drugs are tested at present healthy individuals patients with will soon be presymptomatic disease. hopes high might efficacious prevention or treatment concerns been raised about potential mechanism-based side-effects drugs. inhibition prove to watershed